Bank of Nova Scotia
EGRX

Bank of Nova Scotia’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bank of Nova Scotia’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-85,293
Closed -$2.49M – 1241
2022
Q4 		$2.49M Buy
+85,293
New +$2.71M 0.01% 598

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of Nova Scotia's EGRX Position: Q1 2023 in Review

Bank of Nova Scotia sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 85,293 shares — an estimated $2.49M sold.

Bank of Nova Scotia first reported a position in EGRX in Q4 2022 and held it in 1 quarter. The position peaked at $2.49M in Q4 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • Bank of Nova Scotia reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Bank of Nova Scotia sold 85,293 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.49M.
  • Bank of Nova Scotia first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • Bank of Nova Scotia's Eagle Pharmaceuticals, Inc. position peaked at $2.49M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on Bank of Nova Scotia's 13F filing for Q1 2023, filed 11 May 2023.